Business Context and Reporting Period
This Form 8-K is a current report filed by Hillstream BioPharma, Inc. (trading symbol: HILS) on June 12, 2023. The registrant is a Delaware corporation listed on The Nasdaq Capital Market. The report addresses a specific regulatory notice received from Nasdaq regarding the company's stock price compliance.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance issue. The only financial metric referenced is the stock's closing bid price, which has been below $1.00 per share for the last 30 consecutive business days.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2) due to the minimum bid price requirement. There are no reported changes to the company's operations, capital structure, or financial performance within this document.
Guidance, Outlook, and Risks
- Compliance Timeline: The company has an initial 180-day period (until December 11, 2023) to regain compliance. This requires the closing bid price to meet or exceed $1.00 per share for at least ten consecutive business days.
- Future Actions: If compliance is not met by the initial deadline, the company may qualify for a second 180-day period. Failure to comply during the second period could result in delisting, at which point the company may appeal to a Nasdaq hearings panel.
- Management Intent: Management intends to actively monitor the stock price and may consider implementing available options to regain compliance.
- Risks: The filing highlights risks that the company may fail to meet the minimum bid price requirement, may not qualify for relief, or may ultimately be delisted. Actual results may differ materially from forward-looking statements.
Investor Verification Checklist
- Verify the current closing bid price of HILS stock to assess proximity to the $1.00 threshold.
- Review the company's most recent Form 10-K and 10-Q for detailed financial health and liquidity status, as this 8-K does not provide them.
- Monitor future 8-K filings for announcements of reverse stock splits or other corporate actions intended to address the bid price deficiency.
- Confirm the exact date of the 10-day compliance window if the stock price rises above $1.00.